Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, December 17, 2017

First-in-class New Neuroprotective and Accelerator of Nerve Regeneration Agent Described

With a bit of innovation I could see this as a possibility for stroke rehab. But nothing will be done because we have shit for brains in our fucking failures of stroke associations.
https://www.alphagalileo.org/ViewItem.aspx?ItemId=182036&CultureCode=en




Researchers at the Institute of Neuroscience of the UAB (INc-UAB) have discovered a new pharmacological agent, Neuroheal, which helps to maintain motor neurons alive and accelerates nerve regeneration after traumatic injuries to peripheral nerves. There is currently no drug with these effects being applied in clinical practices.
The research was directed by Caty Casas and included the participation of David Romeo and Xavier Navarro, researchers at the INc-UAB and CIBERNED, and Joaquim Forés of the Hospital Clínic Barcelona.
NeuroHeal was designed to imitate and strengthen neuroprotective mechanisms which naturally command neurons to deal with minor injuries successfully.
The pre-clinical trials indicate that oral administration permits long-lasting maintaining the survival of damaged motor neurons, for at least six months, after peripheral nerve root avulsion, even in cases of delayed surgical reimplantation, as it happens in clinical practices. In addition, the treatment accelerates nerve regeneration, drastically reduces denervation-induced muscular atrophy and increases functional contacts between the nerve and affected muscles.
Researchers at the Institute of Neuroscience of the UAB (INc-UAB) have discovered a new pharmacological agent, Neuroheal, which helps to maintain motor neurons alive and accelerates nerve regeneration after traumatic injuries to peripheral nerves. There is currently no drug with these effects being applied in clinical practices.
“There is currently no pharmacological treatment indicated as an adjuvant therapy to maintain alive a neural population after such a severe injury and until surgical intervention, nor is there any to accelerate nerve regeneration. This new drug acts in both senses”, Caty Casas explains.
Injuries to peripheral nerves are consequence of traffic, work and sportive accidents that can cause nerve sectioning or compression. For example, a digital nerve section or injury in someone who works with dangerous machinery, or a high-energy impact to the shoulder in a motorcycle accident can produce nerve root avulsion in the most vulnerable areas, such as lumbar or brachial roots. The surgical reconstitution may be done days after the accident while the patient is stabilized and diagnosed but during that time, disconnected motor neurons due to nerve traction undergo a fatal and irreparable degenerative process.
In addition, after surgical nerve repairing the surviving motor neurons must regenerate their axons through these same nerves until re-establishing a connection with the muscles they controlled to functional recovering the movements. In this case, it is also a race against time. It can take up to two years for patients to regenerate their nervous circuit. The longer it takes to regenerate, the further muscle atrophy becomes,  hindering a good recovery.
NeuroHeal is a Combination of Two Repurposed Drugs
NeuroHeal is a particular dose combination of two repurposed drugs, Acamprosate and Ribavirin, which are currently used to treat other unrelated diseases. Researchers designed it by using artificial intelligence-based computational tools and systems biology approaches to interpret available biological big data and simulate biological responses to thousands of pharmacological combinations. The combination to conform NeuroHeal presented the best profile amongst all of them. This computational study was conducted thanks to the collaboration with Anaxomics Biotech. 
Researchers have already patented the new drug and hope that it will be used in the near future. “The fact that the two compounds in NeuroHeal are already being used and have demonstrated their pharmacokinetics and safety in humans, allow faster implementation for clinical use”, the researcher concludes.


Attached files

  • The analysis of the the spinal cord ventral horn and sciatic nerve (diagram indicating the areas) through confocal microscope clearly demonstrates that in the reimplantation model (RE), animals treated with NeuroHeal (NH) present more motor axonal ramifications (positive ChAT, in red) and more regenerated fibers (positive GAP43, in magenta) than untreated animals.



No comments:

Post a Comment